Idvynso is a new once-daily, two-drug oral regimen for adults with HIV-1 who are virologically suppressed and have no history of treatment failure.

Randomized trials of long-acting injectable antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) who face challenges with adherence to oral medication are lacking. In step 1 ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is ...

A major study presented today at ESCMID Global 2026 has found that antiretroviral therapy (ART) reduces accelerated ...

Human Immunodeficiency Virus (HIV) is a virus that attacks the body’s immune system, specifically the CD4 (T) cells, which help the body fight off infections. If left untreated, HIV can lead to ...

More than four decades into the HIV epidemic, progress has transformed treatment and prevention, yet the need remains urgent.